| Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome K Röltgen, AE Powell, OF Wirz, BA Stevens, CA Hogan, J Najeeb, ... Science immunology 5 (54), eabe0240, 2020 | 478 | 2020 |
| Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2 SCA Nielsen, F Yang, KJL Jackson, RA Hoh, K Röltgen, GH Jean, ... Cell host & microbe 28 (4), 516-525. e5, 2020 | 227 | 2020 |
| A small molecule targeting mutagenic translesion synthesis improves chemotherapy JL Wojtaszek, N Chatterjee, J Najeeb, A Ramos, M Lee, K Bian, JY Xue, ... Cell 178 (1), 152-159. e11, 2019 | 141 | 2019 |
| Drug design from the cryptic inhibitor envelope CJ Lee, X Liang, Q Wu, J Najeeb, J Zhao, R Gopalaswamy, M Titecat, ... Nature communications 7 (1), 10638, 2016 | 62 | 2016 |
| Structural Basis of the Promiscuous Inhibitor Susceptibility of Escherichia coli LpxC CJ Lee, X Liang, R Gopalaswamy, J Najeeb, ED Ark, EJ Toone, P Zhou ACS chemical biology 9 (1), 237-246, 2014 | 37 | 2014 |
| SARS-CoV-2 antibody responses correlate with resolution of RNAemia but are short-lived in patients with mild illness K Röltgen, OF Wirz, BA Stevens, AE Powell, CA Hogan, J Najeeb, ... MedRxiv, 2020 | 31 | 2020 |
| Curative treatment of severe Gram-negative bacterial infections by a new class of antibiotics targeting LpxC N Lemaître, X Liang, J Najeeb, CJ Lee, M Titecat, E Leteurtre, M Simonet, ... MBio 8 (4), 10.1128/mbio. 00674-17, 2017 | 27 | 2017 |
| Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020; 5 (54) K Roltgen, AE Powell, OF Wirz, BA Stevens, CA Hogan, J Najeeb, ... Epub 2020/12/09. https://doi. org/10.1126/sciimmunol. abe0240 PMID: 33288645, 0 | 11 | |
| Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens J Zhao, CS Cochrane, J Najeeb, D Gooden, C Sciandra, P Fan, ... Science Translational Medicine 15 (708), eadf5668, 2023 | 6 | 2023 |
| Drug design from the cryptic inhibitor envelope. Nat Commun 7: 10638 CJ Lee, X Liang, Q Wu, J Najeeb, J Zhao, R Gopalaswamy, M Titecat, ... DOI, 2016 | 4 | 2016 |
| SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness (preprint) K Röltgen, OF Wirz, BA Stevens, AE Powell, CA Hogan, J Najeeb, ... | 1 | 2020 |
| Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2 (preprint) SCA Nielsen, F Yang, KJL Jackson, RA Hoh, K Röltgen, B Stevens, ... | | 2020 |
| Structure-Guided Design of Novel Therapeutics Targeting Translesion DNA Synthesis and Lipid A Biosynthesis J Najeeb Duke University, 2019 | | 2019 |
| Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC. N Sebbane, X Liang, J Najeeb, CJ Lee, M Titecat, E Leteurtre, M Simonet, ... | | 2017 |
| Curative treatment of severe Gramnegative bacterial infections by a new class of antibiotics targeting LpxC. mBio 8: e00674-17 N Lemaitre, X Liang, J Najeeb, CJ Lee, M Titecat, E Leteurtre, M Simonet, ... | | 2017 |
| Mechanistic Analysis of the Dsl1 Tethering Complex J Najeeb | | 2012 |
